FLUCIPET: Fluciclovine PET/CT in Multiple Myeloma Patients
Sponsor
Oslo University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03966443
Collaborator
(none)
10
1
119.1
0.1
Study Details
Study Description
Brief Summary
Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
10 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose
Actual Study Start Date
:
Mar 1, 2019
Anticipated Primary Completion Date
:
Jan 31, 2020
Anticipated Study Completion Date
:
Jan 31, 2029
Outcome Measures
Primary Outcome Measures
- Comparing of image findings at PET [1 year]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Multiple myeloma patients suitable for ASCT treatment
Exclusion Criteria:
- Patients with contraindications to ASCT treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Oslo University Hosptal | Oslo | Norway | 0424 |
Sponsors and Collaborators
- Oslo University Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Mona-Elisabeth Revheim,
PI, MD, PhD, MHA,
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT03966443
Other Study ID Numbers:
- 2018/2212/REK
First Posted:
May 29, 2019
Last Update Posted:
May 30, 2019
Last Verified:
May 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: